Brooke Pletcher, MD
Family Medicine · Lafayette, INNPI 1609057769
Payments from drug & device makers
Across 207 payments — averaging $13.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$756
- AstraZeneca$404
- Supernus Pharmaceuticals, Inc.$330
- Novo Nordisk$325
- GSK$227
- Lilly USA, LLC$139
- plus $620 from 20 others
What the payments were for
- Food & beverage$2,77699%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $756 |
| AstraZeneca | 25 | $404 |
| Supernus Pharmaceuticals, Inc. | 27 | $330 |
| Novo Nordisk | 37 | $325 |
| GSK | 19 | $227 |
| Lilly USA, LLC | 10 | $139 |
| Johnson & Johnson | 4 | $73 |
| Astellas Pharma US Inc | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Boehringer Ingelheim | 3 | $46 |
| Bayer | 2 | $44 |
| Pfizer | 3 | $41 |
| Boston Scientific | 2 | $39 |
| Dexcom, Inc. | 1 | $29 |
| Amgen | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Merck | 2 | $25 |
| Alkermes, Inc. | 1 | $24 |
| Almatica Pharma LLC | 1 | $21 |
| Exact Sciences | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $13 |
How this compares
$2,802 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 81 | $126,568 |
| EliquisApixaban | 51 | $67,385 |
| MounjaroTirzepatide | 51 | $61,564 |
| JardianceEmpagliflozin | 58 | $60,762 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $24,535 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $21,185 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $18,120 |
| VraylarCariprazine Hcl | 12 | $17,319 |
| TrulicityDulaglutide | 11 | $14,554 |
| FarxigaDapagliflozin Propanediol | 11 | $10,818 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,491 |
| Spiriva HandihalerTiotropium Bromide | 15 | $9,483 |
| Bydureon BciseExenatide Microspheres | 11 | $8,860 |
| Varenicline Tartrate | 21 | $4,997 |
| BelsomraSuvorexant | 11 | $4,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $325 | $126,56881 claims |
| Lilly USA, LLCMounjaro, Trulicity | $139 | $76,11762 claims |
| PfizerEliquis | $41 | $67,38551 claims |
| Boehringer IngelheimJardiance | $46 | $60,76258 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $227 | $38,81860 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $404 | $32,00333 claims |
| AbbVieVraylar, Synthroid | $756 | $18,79235 claims |
| MerckBelsomra, Dulera | $25 | $9,27124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Lafayette
- William BrayLafayette$161K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.